Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Logothetis

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Cancer Research|November 5, 2015
Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate CancerYu-Chen Lee, Song-Chang Lin, Guoyu Yu, et al.
European Urology Oncology|July 12, 2025
Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node MetastasisAmado J Zurita, Rebecca S Tidwell, Brian F Chapin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2020
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate CancerPaymaneh D Malihi, Ryon P Graf, Angel Rodriguez, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate CancerYuanyuan Qiao, Felix Y Feng, Yugang Wang, et al.
Scientific Reports|June 18, 2020
Assessment of Luminal and Basal Phenotypes in Bladder CancerCharles C Guo, Jolanta Bondaruk, Hui Yao, et al.
Urology|May 10, 2025
GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical TrialsAndrew Fang, Daniel E Frigo, Andrew Hahn, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
Oncogene|September 29, 2021
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuelEstefania Labanca, Juan Bizzotto, Pablo Sanchis, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Cancer Research|November 5, 2015
Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate CancerYu-Chen Lee, Song-Chang Lin, Guoyu Yu, et al.
European Urology Oncology|July 12, 2025
Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node MetastasisAmado J Zurita, Rebecca S Tidwell, Brian F Chapin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2020
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate CancerPaymaneh D Malihi, Ryon P Graf, Angel Rodriguez, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate CancerYuanyuan Qiao, Felix Y Feng, Yugang Wang, et al.
Scientific Reports|June 18, 2020
Assessment of Luminal and Basal Phenotypes in Bladder CancerCharles C Guo, Jolanta Bondaruk, Hui Yao, et al.
Urology|May 10, 2025
GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical TrialsAndrew Fang, Daniel E Frigo, Andrew Hahn, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
Oncogene|September 29, 2021
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuelEstefania Labanca, Juan Bizzotto, Pablo Sanchis, et al.
Pageof 9